-
Mashup Score: 22
PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated an
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35
Mitochondrial RNAs attach to chromatin and regulate nuclear transcription in endothelial stress response.
Source: elifesciences.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer - 2 month(s) ago
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs have emerged as a promising modality in cancer treatment over recent years.
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients - 2 month(s) ago
Author links open overlay panel Faisal S. BinHumaid a b, Anshita Goel a, Naheema S. Gordon a, Ben Abbotts a, K.K. Cheng c, Maurice P. Zeegers d, Nicholas D. James e, Waleed M. Altaweel f, Raouf M. Seyam f, Brian F. Meyer b, Roland Arnold a, Douglas G. Ward a â , Richard T. Bryan a â There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients - 2 month(s) ago
Author links open overlay panel Faisal S. BinHumaid a b, Anshita Goel a, Naheema S. Gordon a, Ben Abbotts a, K.K. Cheng c, Maurice P. Zeegers d, Nicholas D. James e, Waleed M. Altaweel f, Raouf M. Seyam f, Brian F. Meyer b, Roland Arnold a, Douglas G. Ward a â , Richard T. Bryan a â There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients - 2 month(s) ago
Author links open overlay panel Faisal S. BinHumaid a b, Anshita Goel a, Naheema S. Gordon a, Ben Abbotts a, K.K. Cheng c, Maurice P. Zeegers d, Nicholas D. James e, Waleed M. Altaweel f, Raouf M. Seyam f, Brian F. Meyer b, Roland Arnold a, Douglas G. Ward a â , Richard T. Bryan a â There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients - 2 month(s) ago
Author links open overlay panel Faisal S. BinHumaid a b, Anshita Goel a, Naheema S. Gordon a, Ben Abbotts a, K.K. Cheng c, Maurice P. Zeegers d, Nicholas D. James e, Waleed M. Altaweel f, Raouf M. Seyam f, Brian F. Meyer b, Roland Arnold a, Douglas G. Ward a â , Richard T. Bryan a â There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
PURPOSE Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC with overall survival (OS) as the primary end point will take approximately a decade to complete. We investigated whether radiographic progression-free survival (rPFS) and clinical PFS (cPFS) are valid surrogates for OS in men with mHSPC and could potentially be used to expedite future phase III clinical trials. METHODS We obtained individual patient data (IPD) from 9 eligible randomized trials comparing treatment regimens (different androgen deprivation therapy [ADT] strategies or ADT plus docetaxel in the control or research arms) in mHSPC. rPFS was defined as the time from random assignment to radiographic progression or death from any cause whichever occurred first; cPFS was defined as the time from random assignment to the date of radiographic progression, symptoms, initiation of
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9ScienceDirect - 2 month(s) ago
Read the latest articles of Actas UrolĂłgicas Españolas at ScienceDirect.com, Elsevierâs leading platform of peer-reviewed scholarly literature
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Masterclass in Bladder Cancer 2024 - 2 month(s) ago
… OncologĂa MĂ©dica AnatomĂa PatolĂłgica CirugĂa EnfermerĂa Farmacia Medicina Nuclear MicrobiologĂa NeumologĂa OncologĂa RadioterĂĄpica RadiologĂa UrologĂa Otra: especificar Hemos procesado el pago correctamente. Revisa tu bandeja de entra da, tienes un email nuestro. Si no lo recibes en menos de 2 minutos, comprueba tu bandeja de
Source: events.tacticsvirtual.netCategories: General Medicine News, Hem/OncsTweet
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 | Journal of Clinical Oncology https://t.co/DvYuVTeIYD